As part of the transaction, the majority of Carestream employees involved in the preclinical in-vivo imaging business will be offered the opportunity to join Bruker. It is anticipated that the transaction will close in the next several weeks.
Carestream will retain the remaining assets of its Molecular Imaging business, including its life science X-ray film product lines and its Gel Logic and Image Station in-vitro imaging equipment product portfolio. Carestream will continue operating its life science X-ray film business, and will continue to support its in-vitro product customers with service and parts. New production of its Gel Logic and Image Station in-vitro products will be discontinued.
Dr. Werner Maas, President of Bruker BioSpin Corporation, commented: "We are excited about adding Carestream's in-vivo imaging systems to our preclinical imaging product portfolio. We believe that Carestream's optical molecular imaging product line will complement our other preclinical solutions, presently consisting of magnetic resonance imaging (MRI), magnetic particle imaging (MPI) and X-ray micro computed tomography (microCT). We also welcome the talented Carestream in-vivo employees to Bruker, and look forward to their contributions."
Related news articles:
- Carestream Health's Profile
About Carestream Health
Carestream Health is a worldwide provider of dental and medical imaging systems and healthcare IT solutions; X-ray film and digital X-ray systems for non-destructive testing; and advanced materials for the precision films and electronics markets.
About Bruker Corporation (NASDAQ: BRKR)
Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.